Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Vulcan secures €2.2BN to fully fund Phase One Lionheart project
07:01am, Wednesday, 03'rd Dec 2025
Vulcan Energy Resources Ltd (ASX:VUL, OTC:VULNF, XETRA:VUL) has secured a €2.2 billion (about A$3.9 billion) financing package to fully fund Phase One of...
Tiziana Life Sciences plans spinout of IL-6 antibody program
09:09am, Tuesday, 02'nd Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately listed public company. Tiziana said its decision follo
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
07:00am, Tuesday, 02'nd Dec 2025
BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies,
Tiziana Life Sciences plans spinout of IL-6 antibody program
04:07am, Tuesday, 02'nd Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately listed...
Nasdaq, Dow gain with Dell and Autodesk boosting tech
06:12am, Wednesday, 26'th Nov 2025
11:10am: Jobless claims fall Initial US jobless claims fell by 6,000 to 216,000 for the week ending November 22, the lowest level since mid-April and well...
Versarien collapses after buyer walks away, leaving company weighing administration
04:33am, Wednesday, 26'th Nov 2025
Versarien PLC (AIM:VRS, OTC:VRSRF) shares sank 38% to 0.006p, valuing the troubled engineering materials group at about £330,000, after the company said a...
Tiziana Life Sciences' Phase 2 foralumab trial joins Healey ALS MyMatch Program
09:24am, Tuesday, 25'th Nov 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted into the ALS My
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
08:30am, Tuesday, 25'th Nov 2025
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, t
Tiziana Life Sciences’ Phase 2 foralumab trial joins Healey ALS MyMatch Program
04:19am, Tuesday, 25'th Nov 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral...
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
08:30am, Thursday, 13'th Nov 2025
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot
09:43am, Friday, 31'st Oct 2025
Tiziana Life Sciences' Foralumab intranasal anti-CD3 targets the Treg–microglia axis. However, their intranasal delivery makes them unique and patient-friendly. Foralumab has a Phase 2 for SPMS, a P
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
07:00am, Wednesday, 29'th Oct 2025
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences to showcase drug candidate at Saudi innovation forum
08:47am, Tuesday, 30'th Sep 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday it has been invited to present at a major biotechnology conference in Riyadh, underscoring Saudi Arabia's push to position itself as a global hub f
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
08:30am, Tuesday, 30'th Sep 2025
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Tiziana Life Sciences stock higher on inflammatory therapy plans
11:44am, Thursday, 25'th Sep 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance development of TZLS-501, an antibody that
